{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:19:54Z","timestamp":1788265194457,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aim<\/jats:title><jats:p>Tegoprazan, a novel potassium\u2010competitive acid blocker, has been approved for <jats:styled-content style=\"fixed-case\"><jats:italic>Helicobacter pylori<\/jats:italic><\/jats:styled-content> eradication in Korea. We compared the efficacy and safety of tegoprazan\u2010 and rabeprazole\u2010based concomitant therapies for <jats:styled-content style=\"fixed-case\"><jats:italic>H.\u00a0pylori<\/jats:italic><\/jats:styled-content> eradication in real\u2010world clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed data from patients with <jats:styled-content style=\"fixed-case\"><jats:italic>H.\u00a0pylori<\/jats:italic><\/jats:styled-content> infection treated with tegoprazan\u2010 or rabeprazole\u2010based concomitant therapies. The primary endpoint was <jats:styled-content style=\"fixed-case\"><jats:italic>H.\u00a0pylori<\/jats:italic><\/jats:styled-content> eradication rate. The secondary endpoint was adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 1474 included patients, 620 and 854 received tegoprazan\u2010 and rabeprazole\u2010based concomitant therapies, respectively. Intention\u2010to\u2010treat analysis showed no significant difference in the eradication rates between the tegoprazan\u2010 and rabeprazole\u2010based concomitant therapy groups (74.7% [95% confidence interval [CI], 71.1\u201378.0%] <jats:italic>vs<\/jats:italic> 72.7% [95% CI, 69.7\u201375.6%], <jats:italic>P<\/jats:italic>\u00a0=\u00a00.400). Per\u2010protocol analysis also demonstrated similar eradication rates for the groups (tegoprazan <jats:italic>vs<\/jats:italic> rabeprazole: 88.0% [95% CI, 85.0\u201390.6%] <jats:italic>vs<\/jats:italic> 85.9% [95% CI, 83.2\u201388.3%], <jats:italic>P<\/jats:italic>\u00a0=\u00a00.288). Although the overall adverse event rate did not differ between groups (tegoprazan <jats:italic>vs<\/jats:italic> rabeprazole, 39.2% <jats:italic>vs<\/jats:italic> 40.6%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.578), abdominal discomfort was less frequent in the tegoprazan group than in the rabeprazole group (1.3 <jats:italic>vs<\/jats:italic> 4.8%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Tegoprazan\u2010 and rabeprazole\u2010based concomitant therapies for <jats:styled-content style=\"fixed-case\"><jats:italic>H.\u00a0pylori<\/jats:italic><\/jats:styled-content> eradication showed comparable efficacy and overall safety. The effect of tegoprazan on dose increases or other regimens, such as bismuth\u2010containing quadruple therapy, should be further evaluated, because the efficacy of tegoprazan\u2010based concomitant therapy may be suboptimal in regions where the clarithromycin resistance rate is high.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jgh.16719","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:38:10Z","timestamp":1724740690000},"page":"2409-2416","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of tegoprazan\u2010 and rabeprazole\u2010based concomitant therapies for <scp><i>Helicobacter pylori<\/i><\/scp> infection: Real\u2010world evidence"],"prefix":"10.1111","volume":"39","author":[{"given":"Byung Wook","family":"Jung","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Hanyang University Guri Hospital, Hanyang University College of Medicine  Guri Republic of Korea"},{"name":"Department of Medicine, Graduate School Yonsei University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-3481","authenticated-orcid":false,"given":"Chan Hyuk","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Chung\u2010Ang University H.C.S. Hyundae Hospital  Namyangju Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1963-7170","authenticated-orcid":false,"given":"Yoon Suk","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.09.004"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s42770-021-00675-0"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1996.37.4.270"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl20288"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01560"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14130"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl220055"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15939"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.05.055"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12279"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2022.345"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12111918"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1098086"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2007.00518.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15438"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2009.125"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311304"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl220218"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15268"},{"key":"e_1_2_6_23_1","unstructured":"Exploratory study to standard triple therapy with tegoprazan (by dose) inH. Pyloripositive patients (ClinicalTrials.gov ID: NCT05933031). Available from URL:https:\/\/clinicaltrials.gov\/study\/NCT05933031."},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-1076-x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.244202"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268686"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000524078"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12592"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl220429"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2008.02.030"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.16719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:46:09Z","timestamp":1744253169000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.16719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/jgh.16719"],"URL":"https:\/\/doi.org\/10.1111\/jgh.16719","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"assertion":[{"value":"2024-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}